Scholarlink

<p>Hormone receptor-positive, HER2-negative metastatic breast cancer care is rapidly moving from sequencing to a precision framework. First-line CDK4/6 inhibitor-based therapy remains the standard of care, but a new wave of trials shifts the focus to identifying who benefits and when biology should inform treatment optimization. Incorporating biomarker-selected intensification and embedding PROs, PREMs, and quality-adjusted endpoints more closely align treatment with what patients value.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Beyond timing, toward precision: insights from CDK4/6 inhibitor trials in metastatic breast cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月12日

查看全文
  • Serena Di Cosimo,
  • Giovanni Apolone

摘要

Hormone receptor-positive, HER2-negative metastatic breast cancer care is rapidly moving from sequencing to a precision framework. First-line CDK4/6 inhibitor-based therapy remains the standard of care, but a new wave of trials shifts the focus to identifying who benefits and when biology should inform treatment optimization. Incorporating biomarker-selected intensification and embedding PROs, PREMs, and quality-adjusted endpoints more closely align treatment with what patients value.